Charles Schwab
SYRE icon

Charles Schwab’s Spyre Therapeutics SYRE Stock Holding History

Charles Schwab’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58M Buy
652,958
+90,305
+16% +$6.59M 0.01% 1148
2026
Q1 		$28.4M Sell
562,653
-11,969
-2% -$451K ﹤0.01% 1523
2025
Q4 		$18.8M Buy
574,622
+149,277
+35% +$3.9M ﹤0.01% 1785
2025
Q3 		$7.13M Buy
425,345
+6,842
+2% +$112K ﹤0.01% 2280
2025
Q2 		$6.26M Buy
418,503
+35,867
+9% +$531K ﹤0.01% 2235
2025
Q1 		$6.17M Buy
382,636
+2,986
+0.8% +$62.1K ﹤0.01% 2182
2024
Q4 		$8.84M Buy
379,650
+46,375
+14% +$1.36M ﹤0.01% 2072
2024
Q3 		$9.8M Buy
333,275
+235,094
+239% +$6.55M ﹤0.01% 2032
2024
Q2 		$2.31M Buy
98,181
+83,181
+555% +$2.81M ﹤0.01% 2662
2024
Q1 		$569K Buy
+15,000
New +$435K ﹤0.01% 2973
2022
Q2 		– Sell
-4,272
Closed -$246K – 3637
2022
Q1 		$246K Buy
4,272
+293
+7% +$24.6K ﹤0.01% 3271
2021
Q4 		$473K Hold
3,979
– – ﹤0.01% 3164
2021
Q3 		$791K Sell
3,979
-252
-6% -$44.1K ﹤0.01% 2967
2021
Q2 		$737K Sell
4,231
-200
-5% -$36.3K ﹤0.01% 3036
2021
Q1 		$878K Sell
4,431
-66
-1% -$12.7K ﹤0.01% 2900
2020
Q4 		$885K Buy
4,497
+271
+6% +$56.2K ﹤0.01% 2812
2020
Q3 		$750K Sell
4,226
-128
-3% -$23.7K ﹤0.01% 2754
2020
Q2 		$1.01M Buy
4,354
+1,932
+80% +$368K ﹤0.01% 2626
2020
Q1 		$283K Buy
2,422
+37
+2% +$6.29K ﹤0.01% 2914
2019
Q4 		$456K Hold
2,385
– – ﹤0.01% 2854
2019
Q3 		$459K Hold
2,385
– – ﹤0.01% 2833
2019
Q2 		$409K Buy
2,385
+605
+34% +$105K ﹤0.01% 2904
2019
Q1 		$359K Buy
1,780
+134
+8% +$27.9K ﹤0.01% 2887
2018
Q4 		$309K Buy
1,646
+434
+36% +$92.1K ﹤0.01% 2926
2018
Q3 		$290K Hold
1,212
– – ﹤0.01% 3012
2018
Q2 		$321K Buy
+1,212
New +$298K ﹤0.01% 2935

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Charles Schwab's SYRE Position: Q2 2026 in Review

Charles Schwab increased its Spyre Therapeutics (SYRE) stake by 16% in Q2 2026, buying an estimated $6.59M and bringing the position to 652,958 shares worth $58M. The position accounts for 0.01% of the portfolio, ranked #1148.

Charles Schwab first reported a position in SYRE in Q2 2018 and has held it in 26 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Charles Schwab held 652,958 shares of Spyre Therapeutics worth $58M as of Q2 2026.
  • Charles Schwab bought 90,305 Spyre Therapeutics shares in Q2 2026, an estimated $6.59M.
  • Spyre Therapeutics made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1148 holding.
  • Charles Schwab first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 26 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.